272 related articles for article (PubMed ID: 11346862)
1. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Wellington K; Goa KL
Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
[TBL] [Abstract][Full Text] [Related]
5. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
6. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
7. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
Coleman RE; Seaman JJ
Semin Oncol; 2001 Apr; 28(2 Suppl 6):11-6. PubMed ID: 11346860
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
11. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
14. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
17. Management of bone metastases in breast cancer.
Lipton A
Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
19. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Harvey HA
Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
